Announcement: Andrew (Andy) Fenny Named President of Pace Life Sciences
Pace Life Sciences, the life sciences division of Pace, has appointed Andrew (Andy) Fenny as its President.
Fenny emphasized the strong foundation of scientific expertise at Pace, noting, “As life sciences organizations face evolving challenges, Pace is well-positioned to provide integrated support, allowing these organizations to advance with confidence.”
Ken Beyer, CEO of Pace, commented on Fenny’s appointment, stating, “In these complex market conditions, our customers require more than just results. Andy’s leadership will enhance our capability to support companies throughout the product lifecycle, ultimately benefiting patients waiting for transformative treatments.”
About Andy Fenny
As President, Fenny will oversee the division’s operations, enhance collaboration among Pace Life Sciences’ eight sites, and guide customer service delivery from development to commercialization. He aims to expand the organization’s support for pharmaceutical and biotech clients.
With over 20 years of leadership experience, Fenny joins Pace Life Sciences from SK pharmteco, where he was Chief Commercial Officer. Prior to that, he served as Chief Business Officer at FUJIFILM Diosynth Biotechnologies, focusing on commercial strategy and business development.
About Pace Life Sciences
Pace Life Sciences consists of eight sites across the U.S., catering to a wide range of pharmaceutical and biotech companies. The Analytical Center of Excellence located in Research Triangle Park offers various testing and development services supported by advanced instrumentation. Pace Life Sciences is a portfolio company of Leonard Green & Partners and Aurora Capital Partners.
